Case Type: Mergers & Acquisitions

Embark Technology, Inc. (NASDAQ: EMBK), relating to its proposed sale to Applied Intuition, Inc. Under the terms of the agreement, EMBK shareholders are expected to receive $2.88 in cash per share they own.

GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA), relating to its proposed sale to Fall Line Capital LLC. Under the terms of the agreement, GRNA shareholders are expected to receive $0.30 in cash per share they own.

Franchise Group, Inc. (NASDAQ: FRG), relating to its proposed sale to its CEO, Brian Kahn, members of its senior management team, and a consortium including B. Riley Financial, Inc. and Irradiant Partners. Under the terms of the agreement, FRG shareholders are expected to receive $30.00 in cash per share they own.

Akerna Corp. (NASDAQ: KERN), relating to its proposed merger with Gryphon Digital Mining, Inc. Under the terms of the agreement, KERN shareholders are expected to own approximately 7.5% of the combined company.

VectivBio Holding AG (NASDAQ: VECT), relating to its proposed sale to Ironwood Pharmaceuticals Inc. Under the terms of the tender offer, VECT shareholders are expected to receive $17.00 in cash per share they own.

Amedisys, Inc. (NASDAQ: AMED), relating to its proposed merger with Option Care Health, Inc. Under the terms of the agreement, AMED shareholders are expected to receive 3.0213 share of Option Care per share they own.

Home Point Capital Inc. (NASDAQ: HMPT), relating to its proposed sale to Mr. Cooper Group Inc.

CTI Biopharma Corp, Inc. (NASDAQ: CTIC), relating to its proposed sale to Swedish Orphan Biovitrum AB. Under the terms of the agreement, CTIC shareholders are expected to receive $9.10 in cash per share they own.

Magellan Midstream Partners, L.P. (NYSE: MMP), relating to its proposed sale to ONEOK, Inc. Under the terms of the agreement, MMP shareholders are expected to receive $25.00 in cash and 0.6670 shares of ONEOK per share they own.

Magenta Therapeutics, Inc. (NASDAQ: MGTA), relating to its proposed merger with Dianthus Therapeutics, Inc. Under the terms of the agreement, MGTA shareholders are expected to own approximately 21.3% of the combined company